Rainer Kutzner

numares AG develops and markets new analytic and diagnostic tests based on nuclear magnetic resonance spectroscopy. It offers in-vitro-diagnostic tests with the CE marking for high-throughput use in clinical practice and medical research. The firm?s test applications provide valuable information on the disease status of patients in the indication areas of cardiovascular diseases, nephrology and oncology. The company was founded in April 2004 and is headquartered in Regensburg, Germany.

numares AG develops and markets new analytic and diagnostic tests based on nuclear magnetic resonance spectroscopy. It offers in-vitro-diagnostic tests with the CE marking for high-throughput use in clinical practice and medical research. The firm?s test applications provide valuable information on the disease status of patients in the indication areas of cardiovascular diseases, nephrology and oncology. The company was founded in April 2004 and is headquartered in Regensburg, Germany.

numares AG develops and markets new analytic and diagnostic tests based on nuclear magnetic resonance spectroscopy. It offers in-vitro-diagnostic tests with the CE marking for high-throughput use in clinical practice and medical research. The firm?s test applications provide valuable information on the disease status of patients in the indication areas of cardiovascular diseases, nephrology and oncology. The company was founded in April 2004 and is headquartered in Regensburg, Germany.

numares AG develops and markets new analytic and diagnostic tests based on nuclear magnetic resonance spectroscopy. It offers in-vitro-diagnostic tests with the CE marking for high-throughput use in clinical practice and medical research. The firm?s test applications provide valuable information on the disease status of patients in the indication areas of cardiovascular diseases, nephrology and oncology. The company was founded in April 2004 and is headquartered in Regensburg, Germany.

numares AG develops and markets new analytic and diagnostic tests based on nuclear magnetic resonance spectroscopy. It offers in-vitro-diagnostic tests with the CE marking for high-throughput use in clinical practice and medical research. The firm?s test applications provide valuable information on the disease status of patients in the indication areas of cardiovascular diseases, nephrology and oncology. The company was founded in April 2004 and is headquartered in Regensburg, Germany.